Curis (CRIS) Reports In-Line Q1 EPS

Go back to Curis (CRIS) Reports In-Line Q1 EPS

Curis Provides First Quarter 2023 Business Update

May 4, 2023 4:01 PM EDT

Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3

Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Development Officer

Strong balance sheet with $71.8 million in cash and investments; cash runway into 2025

Management to host conference call today at 4:30 p.m. ET

LEXINGTON, Mass., May 4, 2023 /PRNewswire/ --... More